About 90 per cent of Sinovac Biotech Ltd employees and their families have taken an experimental coronavirus vaccine developed by the Chinese firm under the country’s emergency use programme, its chief executive said on Sunday.

Sinovac, whose CoronaVac is in Phase 3 clinical trials and has been included in the emergency scheme, offered the candidate vaccine to approximately 2,000 to 3,000 employees and their families on a voluntary basis, CEO Yin Weidong said.